Chinook Therapeutics Profit Margin

The latest profit margin for KDNY is -4158.15% as of June 2023. That compares with -170.15% in the prior-year period — down 2343.9% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Chinook Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, KDNY's profit margin moved from -170.15% to -4158.15% — a 2343.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Chinook Therapeutics's valuation or profitability profile.

Against Healthcare companies, KDNY currently prints -4158.15% for profit margin, while the sector average sits near 14.34%. That is roughly 29087.2% below the sector mean. Large gaps often invite a closer look at Chinook Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Chinook Therapeutics converts resources into returns. At -4158.15%, KDNY may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -170.15% in the prior-year period — down 2343.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting KDNY's profit margin (-4158.15%), review year-over-year change from -170.15%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.